Business Context and Reporting Period
This Form 8-K filing by AnaptysBio, Inc. (ANAB) covers the event date of November 21, 2025. The report details a corporate action regarding the company's capital structure and shareholder return strategy.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The primary financial data points relate to the stock repurchase program:
- Additional Authorization: $100.0 million authorized for new share repurchases.
- Remaining Balance (Prior Plan): $6.4 million available under the existing $75.0 million plan as of November 20, 2025.
- Total Shares Repurchased to Date: 3,443,188 shares.
- Repurchase Impact: Represents 11.2% of shares outstanding prior to the initiation of the Stock Repurchase Plan.
Material Changes
The Board of Directors authorized an amendment to the Stock Repurchase Plan previously approved in March 2025. This amendment increases the total capacity for share buybacks by an additional $100.0 million, supplementing the remaining $6.4 million from the prior authorization.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, forward-looking outlook statements, or specific risk factors beyond the standard disclosure of the repurchase activity. The company indicated that the repurchases may be made from time to time in the open market or through privately negotiated transactions, subject to market conditions and other factors.
Investor Verification Checklist
- Verify the total aggregate amount authorized for repurchases ($106.4 million) and the remaining balance available for future execution.
- Confirm the current share count to assess the dilution or concentration impact of the 3,443,188 shares already repurchased.
- Review the attached Press Release (Exhibit 99.1) for specific details on the timing and methodology of future repurchases.
- Check subsequent filings for actual execution of the new $100.0 million authorization.